Effect of Eradication of Helicobacter pylori on the Histology and Cellular Phenotype of Gastric Intestinal Metaplasia

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 4, 2008, Pages 409-417

  Watari, Jiro ^a,b   Das, Koushik K ^b   Amenta, Peter S ^b   Tanabe, Hiroki ^a   Tanaka, Atsumi ^a   Geng, Xin ^b   Lin, Jim J C ^c   Kohgo, Yutaka ^a   Das, Kiron M ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Department of Medicine   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; MONOCLONAL ANTIBODY; MUCIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER RISK; CELL; CHRONIC GASTRITIS; ENDOSCOPY; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; INTESTINE METAPLASIA; JAPAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RISK REDUCTION; STOMACH CANCER; THERAPY EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-INFECTIVE AGENTS; ANTIBODIES; BIOPSY; CHRONIC DISEASE; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; TROPOMYOSIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41349088798     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.12.044     Document Type: Article

References (65)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54 (1993) 594-606
2. Warren J.R., and Marshall B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1 (1983) 1273-1275
3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19 (1995) S37-S43
4. Huang J.Q., Sridhar S., Chen Y., et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114 (1998) 1169-1179
5. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 13 (1999) 851-856
6. You W.C., Zhang L., Gail M.H., et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 92 (2000) 1607-1612
7. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001) 784-789
8. Take S., Mizuno M., Ishiki K., et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 100 (2005) 1037-1042
9. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004) 187-194
10. Correa P., and Shiao Y.H. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54 (1994) 1941s-1943s
11. Filipe M.I., Munoz N., Matko I., et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57 (1994) 324-329
12. Genta R.M., and Lew GM Graham D.Y. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 6 (1993) 281-289
13. Uemura N., Mukai T., Okamoto S., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 639-642
14. Nardone G., Staibano S., Rocco A., et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 44 (1999) 789-799
15. Sung J.J., Lin S.R., Ching J.Y., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 119 (2000) 7-14
16. Ohkusa T., Fujiki K., Takashimizu I., et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 134 (2001) 380-386
17. Kokkola A., Sipponen P., Rautelin H., et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 16 (2002) 515-520
18. Correa P., Fontham E.T.H., Bravo J.C., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92 (2000) 1881-1888
19. Ley C., Mohar A., Guarner J., et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 13 (2004) 4-10
20. Mera R., Fontham E.T., Bravo L.E., et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 54 (2005) 1536-1540
21. You W.C., Brown L.M., Zhang L., et al. Randomized double-blind factorial of three treatments to reduce the precancerous gastric lesion. J Natl Cancer Inst 98 (2006) 974-983
22. Witteman E.M., Mravunac M., Becx M.J., et al. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. J Clin Pathol 48 (1995) 250-256
23. Forbes G.M., Warren J.R., Glaser M.E., et al. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 11 (1996) 670-673
24. van der Hulst R.W., van der Ende A., Dekker F.W., et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology 113 (1997) 25-30
25. Hibi K., Mitomi H., Koizumi W., et al. Enhanced cellular proliferation and p53 accumulation in gastric mucosa chronically infected with Helicobacter pylori. Am J Clin Pathol 108 (1997) 26-34
26. Satoh K., Kimura K., Takimoto T., et al. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 3 (1998) 236-240
27. Tucci A., Poli L., Tosetti C., et al. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 93 (1998) 1425-1431
28. Tepes B., Kavcic B., Zaletel L.K., et al. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 188 (1999) 24-29
29. El-Omar E.M., Oien K., Murray L.S., et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 118 (2000) 22-30
30. Kim N., Lim S.H., Lee K.H., et al. Long-term effects of Helicobacter pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig Dis Sci 45 (2000) 1754-1762
31. Kuipers E.J., Nelis G.F., Klinkenberg-Knol E.C., et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53 (2004) 12-20
32. Tanaka A., Watari J., Tanabe H., et al. Effect of eradication of Helicobacter pylori on genetic instabilities in gastric intestinal metaplasia. Aliment Pharmacol Ther 24 Suppl 4 (2006) 194-202
33. Das K.M., Sakamaki S., Vecchi M., et al. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol 139 (1987) 77-84
34. Halstensen T.S., Das K.M., and Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut 34 (1993) 650-657
35. Das K.M., Prasad I., Garla S., et al. Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med 120 (1994) 753-756
36. Griffel L.H., Amenta P.S., and Das K.M. Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus. Dig Dis Sci 45 (2000) 40-48
37. Onuma E.K., Amenta P.S., Jukkola A.F., et al. A phenotypic change of small intestinal epithelium to that of colonocytes in small intestinal adenomas and adenocarcinomas. Am J Gastroenterol 96 (2001) 2480-2485
38. Filipe M.I., and Jass J.R. Intestinal metaplasia subtypes and cancer risk. In: Filipe M.I., and Jass J.R. (Eds). Gastric carcinoma (1986), Churchill Livingstone, Edinburgh 212-236
39. Mirza Z.K., Das K.K., Slate J., et al. Gastric intestinal metaplasia as detected by a novel biomarker is highly associated with gastric adenocarcinoma. Gut 52 (2003) 807-812
40. Lin J.L., Geng X., Bhattacharya S.D., et al. Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology 123 (2002) 152-162
41. Lees-Miller J.P., and Helfman D.M. The molecular basis for tropomyosin isoform diversity. Bioessays 13 (1991) 429-437
42. Pittenger M.F., and Helfman D.M. In vitro and in vivo characterization of four fibroblast tropomyosins produced in bacteria: TM-2, TM-3, TM-5a, and TM-5b are co-localized in interphase fibroblasts. J Cell Biol 118 (1992) 841-858
43. Lin J.J., Warren K.S., Wamboldt D.D., et al. Tropomyosin isoforms in nonmuscle cells. Int Rev Cytol 170 (1997) 1-38
44. Novy R.E., Lin J.L., Lin C.S., et al. Human fibroblast tropomyosin isoforms: characterization of cDNA clones and analysis of tropomyosin isoform expression in human tissues and in normal and transformed cells. Cell Motil Cytoskeleton 25 (1993) 267-281
45. Das K.M., Dasgupta A., Mandal A., et al. Autoimmunity to cytoskeletal protein tropomyosin: a clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 150 (1993) 2487-2493
46. Geng X., Biancone L., Dai H.H., et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114 (1998) 912-922
47. Onuma E.K., Amenta P.S., Ramaswamy K., et al. Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5. Clin Exp Immunol 121 (2000) 466-471
48. Biancone L., Mandal A., Yang H., et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology 109 (1995) 3-12
49. Sakamaki S., Takayanagi N., Yoshizaki N., et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells. Gut 47 (2000) 236-241
50. Taniguchi M., Geng X., Glazier K.D., et al. Cellular immune response against tropomyosin isoform 5 in ulcerative colitis. Clin Immunol 101 (2001) 289-295
51. In: Parkin D.M., Whelan S.L., Ferlay J., et al. (Eds). Cancer incidence in five countries Vol. VII (1997), International Agency for Research on Cancer, World Health Organization and International Association of Cancer Registries, Lyon ARC Scientific Publication no. 143.
52. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20 (1996) 1161-1181
53. Rugge M., Correa P., Dixon M.F., et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 24 (2000) 167-176
54. Farinati F., Foschia F., Di Mario F., et al. H. pylori eradication and gastric precancerous lesions. Gastroenterology 115 (1998) 512-514
55. Sakaki N., Kozawa H., Egawa N., et al. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther 16 (2002) 198-203
56. Asaka M., Sugiyama T., Nobuta A., et al. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 6 (2001) 294-299
57. Correa P., Haenszel W., Cuello C., et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50 (1990) 4737-4740
58. Das-Bhattacharya S., Walton K., Watari J., et al. Expression of a novel human tropomyosin isoform, TC22, in gastric intestinal metaplasia associated with gastric carcinoma. Gastroenterology 122 (2002) A129
59. Wu M.S., Shun C.T., Lee W.C., et al. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 78 (1998) 971-973
60. Shiao Y.H., Rugge M., Correa P., et al. p53 alteration in gastric precancerous lesions. Am J Pathol 144 (1994) 511-517
61. Imatani A., Sasano H., Yabuki N., et al. In situ analysis of tissue dynamics and p53 expression in human gastric mucosa. J Pathol 179 (1996) 39-42
62. Hamamoto T., Yokozaki H., Semba S., et al. Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J Clin Pathol 50 (1997) 841-846
63. Jones N.L., Shannon P.T., Cutz E., et al. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection. Am J Pathol 151 (1997) 1695-1703
64. Satoh K., Kihira K., Kawata H., et al. p53 expression in the gastric mucosa before and after eradication of Helicobacter pylori. Helicobacter 6 (2001) 31-36
65. Watari J., Tanaka A., Tanabe H., et al. K-ras mutations and cell kinetics in Helicobacter pylori associated gastric intestinal metaplasia: a comparison before and after eradication in patients with chronic gastritis and gastric cancer. J Clin Pathol 60 (2007) 921-926